Please Note - Streaming News is only available to subscribers to the Active Level and above
RNS News Service
I confirm that I am accessing this story in my capacity as a private investor and NOT for professional purposes.
Form 38.5(b) - Willis Towers Watson PLC- Amendment
RNS
RNS Number : 9774C
Goldman Sachs & Co. LLC
22 October 2020
Amendment - due to the amendment of Equity transactions, the disclosure made on 20 October for dealings on 19 October has been updated. Sections 2(a) and 3(a) have been updated.
FORM 38.5(b)
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNISED INTERMEDIARY STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY
1. KEY INFORMATION
Name of exempt principal trader
GOLDMAN SACHS & CO. LLC
Company dealt in
WILLIS TOWERS WATSON PLC
Class of relevant security to which the dealings being disclosed relate (Note1)
USD 0.000304635 ordinary shares
Date of dealing
19 October 2020
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 2)
Long
Short
Number
(%)
Number
(%)
(1) Relevant securities
526,639.912
(0.40)
298,666.912
(0.23)
(2) Derivatives (other than options)
50,873
(0.03)
374,217
(0.29)
(3) Options and agreements to purchase/sell
0
(0.00)
0
(0.00)
Total
577,512.912
(0.44)
672,883.912
(0.52)
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 2)
Class of relevant security:
Long
Short
Number
(%)
Number
(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total
3. DEALINGS (Note 3)
(a) Purchases and sales
Purchase/sale
Number of relevant securities
Price per unit (Note 4)
Purchase
613
212.7100 USD
Purchase
3,871
212.7100 USD
Purchase
2
212.7100 USD
Purchase
91
212.7100 USD
Purchase
385
212.7100 USD
Purchase
12
212.8300 USD
Purchase
2
217.1300 USD
Purchase
1
217.1500 USD
Sale
100
212.6800 USD
Sale
409
212.7100 USD
Sale
1
212.7100 USD
Sale
777
212.7100 USD
Sale
329
212.7100 USD
Sale
576
212.7100 USD
Sale
4,405
212.7100 USD
Sale
20
212.7100 USD
Sale
10
214.9300 USD
Sale
90
214.9300 USD
Sale
13
214.9400 USD
Sale
87
214.9400 USD
Sale
85
214.9500 USD
Sale
100
214.9700 USD
Sale
3
215.0150 USD
Sale
4
215.0150 USD
Sale
8
215.0150 USD
Sale
100
215.0150 USD
Sale
15
215.1000 USD
Sale
85
215.1000 USD
Sale
100
215.2000 USD
Sale
100
215.2100 USD
Sale
100
215.2100 USD
Sale
95
215.3300 USD
Sale
5
215.3950 USD
Sale
100
215.3950 USD
Sale
100
215.4700 USD
Sale
100
215.4700 USD
Sale
9
215.4700 USD
Sale
1
215.4800 USD
Sale
100
215.4800 USD
Sale
100
215.4800 USD
Sale
21
215.4800 USD
Sale
10
215.5100 USD
Sale
1
215.5100 USD
Sale
99
215.5200 USD
Sale
100
215.5200 USD
Sale
70
215.5450 USD
Sale
92
215.5450 USD
Sale
8
215.5450 USD
Sale
89
215.5450 USD
Sale
57
215.6200 USD
Sale
79
215.6200 USD
Sale
21
215.6200 USD
Sale
43
215.6200 USD
Sale
10
215.6700 USD
Sale
100
215.6800 USD
Sale
90
215.7900 USD
Sale
25
215.8100 USD
Sale
100
215.8200 USD
Sale
100
215.9300 USD
Sale
15
215.9350 USD
Sale
60
215.9350 USD
Sale
10
215.9900 USD
Sale
90
215.9900 USD
Sale
100
216.0300 USD
Sale
100
216.0350 USD
Sale
5
216.0500 USD
Sale
48
216.0500 USD
Sale
47
216.0500 USD
Sale
50
216.0600 USD
Sale
50
216.0900 USD
Sale
50
216.1050 USD
Sale
100
216.1100 USD
Sale
152
216.1700 USD
Sale
48
216.2650 USD
Sale
100
216.3900 USD
Sale
20
216.3900 USD
Sale
180
216.4200 USD
Sale
7
216.4400 USD
Sale
10
216.5600 USD
Sale (Loan Adjust)
384
N/A
Sale (Loan Adjust)
9
N/A
Purchase (Loan Partial Return)
384
N/A
Sale (Loan New)
10,648
N/A
Purchase (Loan Full Return)
10,648
N/A
(b) Derivatives transactions (other than options transactions)
Product name, e.g. CFD
Nature of transaction (Note 5)
Number of relevant securities (Note 6)
Price per unit (Note 4)
CFD
Reducing a short position
3,910
215.5601 USD
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name,e.g. call option
Writing, selling, purchasing, varying etc.
Number of securities to which the option relates (Note 7)
Exercise price
Type, e.g. American, European etc.
Expiry date
Option money paid/received per unit (Note 4)
(ii) Exercising
Product name,e.g. call option
Number of securities
Exercise price per unit (Note 4)
(d) Other dealings (including transactions in respect of new securities) (Note 3)
Nature of transaction (Note 7)
Details
Price per unit (if applicable) (Note 4)
4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
NONE
Is a Supplemental Form 8 attached? (Note 9) YES
Date of disclosure
22 October 2020
Contact name
Kashif Rafiq and Papa Lette
Telephone number
+44(20) 7051 0547 / +44(20) 7774 7442
Name of offeree/offeror with which connected
WILLIS TOWERS WATSON PLC
Nature of connection (Note 9)
Advisor to Offeree
SUPPLEMENTAL FORM 38.5(b)
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DETAILS OF OPEN POSITIONS
OPEN POSITIONS (Note 1)
Product name,e.g. call option
Written or purchased
Number of relevant securities to which the option or derivative relates
Exercise price (Note 2)
Type, e.g. American, European etc.
Expiry date
Swap
Sold
185
0.0000
N/A
23/09/2021
Swap
Sold
273
0.0000
N/A
04/01/2021
Swap
Sold
44,335
0.0000
N/A
14/04/2021
Swap
Sold
69,482
0.0000
N/A
14/04/2021
Notes
1. Where there are open option positions or open derivative positions (except for CFDs), full details should be given. Full details of any existing agreements to purchase or to sell must also be given on this form.
2. For all prices and other monetary amounts, the currency must be stated.
For full details of disclosure requirements, see Rules 8 and 38.5 of the Rules. If in doubt, consult the Panel.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.